Real-World Insight on Apremilast Therapy in Patients with Plaque Psoriasis: Indian Experience

INTRODUCTION: Psoriasis is an immune-mediated inflammatory skin disorder, which follows a chronic course. Apremilast is a novel phosphodiesterase 4 (PDE4) inhibitor, approved by US-FDA for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis. A majority of the data related to...

Descripción completa

Detalles Bibliográficos
Autores principales: De, Abhishek, Das, Sudip, Dhoot, Dhiraj, Sarda, Aarti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640799/
https://www.ncbi.nlm.nih.gov/pubmed/33165422
http://dx.doi.org/10.4103/ijd.IJD_194_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640799/
https://www.ncbi.nlm.nih.gov/pubmed/33165422
http://dx.doi.org/10.4103/ijd.IJD_194_19

Ejemplares similares